Peng Yuanli, Yan Haozhen, Zhang Jinsong, Peng Ruihao, Feng Xiangning, Su Jiayue, Yi Huaimin, Lu Yuying, Chen Zeliang
One Health Center of Excellence for Research and Training, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, China; NMPA Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, 510080, China; Key Laboratory of Tropical Diseases Control, Sun Yat-Sen University, Ministry of Education, Guangzhou, 510080, China.
One Health Center of Excellence for Research and Training, School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, China; NMPA Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological Products, Guangzhou, 510080, China; Key Laboratory of Tropical Diseases Control, Sun Yat-Sen University, Ministry of Education, Guangzhou, 510080, China; Key Laboratory of Zoonose Prevention and Control at Universities of Inner Mongolia Autonomous Region, Medical College, Inner Mongolia Minzu University, Tongliao, 028000, P. R. China; Key Laboratory of Livestock Infectious Diseases, Ministry of Education, Shenyang Agricultural University, Shenyang, 110866, China.
Vaccine. 2024 Feb 6;42(4):732-737. doi: 10.1016/j.vaccine.2023.12.079. Epub 2024 Jan 13.
Foot-and-mouth disease (FMD) is an acute zoonosis causes significant economic losses. Vaccines able to stimulate efficient protective immune responses are urgently needed. In this study, Escherichia coli-derived recombinant VP1 of serotype A and O FMD virus (FMDV) was conjugated to thermostable scaffold lumazine synthase (LS) or Quasibacillus thermotolerans encapsulin (QtEnc) using a robust plug-and-display SpyTag/SpyCatcher system to generate multimeric nanovaccines. These nanovaccines induced highly potent antibody responses in vaccinated mice. On day 14 after the first immunisation, antibody titres were approximately 100 times higher than those of monomer antigens. Both vaccines induced high and long-term IgG antibody production. Moreover, the QtEnc-VP1 nanovaccine induced higher antibody titres than the LS-VP1 nanovaccine. The nanovaccines also induced Th1-biased immune responses and higher levels of neutralising antibodies. These data indicated that FMDV nanovaccines generated by conjugating VP1 with a thermostable scaffold are highly immunogenic and ideal candidates for FMDV control in low-resource areas.
口蹄疫(FMD)是一种急性人畜共患病,会造成重大经济损失。迫切需要能够刺激有效保护性免疫反应的疫苗。在本研究中,利用强大的“插入并展示”SpyTag/SpyCatcher系统,将A型和O型口蹄疫病毒(FMDV)的大肠杆菌衍生重组VP1与热稳定支架蛋白核黄素合酶(LS)或耐热栖热芽孢杆菌封装蛋白(QtEnc)偶联,以生成多聚纳米疫苗。这些纳米疫苗在接种小鼠中诱导了高效的抗体反应。首次免疫后第14天,抗体滴度比单体抗原高约100倍。两种疫苗均诱导了高水平且长期的IgG抗体产生。此外,QtEnc-VP1纳米疫苗诱导的抗体滴度高于LS-VP1纳米疫苗。这些纳米疫苗还诱导了以Th1为主的免疫反应和更高水平的中和抗体。这些数据表明,通过将VP1与热稳定支架偶联产生的FMDV纳米疫苗具有高度免疫原性,是资源匮乏地区控制FMDV的理想候选疫苗。